File No. CT/115/23-DCG(I)

सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION(Headquarter)(Directorate General ofHealthServices) Ministry of Health & Family Welfare
FDA Bhavan
ITO, KotlaRoad New Delhi - 110002 (Delhi) Phone No.:91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/23/000115

To,

M/s. AstraZeneca Pharma India Limited,
Block NO 1, 12th Floor Manyata Embassy,
Business Park, Rachenahalli Outer Ring Road,
Bangalore, Karnataka (India) – 560045.

Sir,

With reference to your application No. GCT/CT04/FF/2023/39544 (GCT/115/23) dated 09-09-2023, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **"A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)" Protocol No: D361DC00001, Amendment No. 4.0, Version 5.0 dated 24/May/2023 & Clinical Study Protocol - Addendum IND – 1 (Version 1.0 dated 23/Aug/2023) with a total of up-to 50 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) **The applicant shall perform Phase III part of the proposed global clinical study and Phase-Ib part of the study will not be applicable in India;**

(ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study datagenerated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27690 41015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=B57F5E47D94098SD8F03BDC902D0E1 FE73C5A12A1A120E494FA5101124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.01.08 10:14:51 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)&
Central Licencing Authority
Stamp

File No. CT/115/23-DCG(I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. AstraZeneca Pharma India Limited, Block NO 1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Bangalore (India) - 560045** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No: D361DC00001, Amendment No. 4.0, Version 5.0 dated 24/May/2023 & Clinical Study Protocol - Addendum IND – 1 (Version 1.0 dated 23/Aug/2023)** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769041015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=[illegible]0E1FE73CFA12A1A126EA94FA57011124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.01.08 10:56:52 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)&
Central Licencing Authority

Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Capivasertib (AZD5363)film-coated tablet 160 mg Capivasertib (AZD5363) film-coated tablet 200 mg
Therapeutic class:	Anticancer
Dosage form:	Tablets
Composition:	Capivasertib =160.0000 milligram(mg),In House Specification, Active; Microcrystalline cellulose =128.4000 milligram (mg), Ph. Eur Inactive; Calcium hydrogen phosphate/Dibasic calcium phosphate = 85.6000 milligram (mg), Ph. Eur Inactive; Croscarmellose Sodium =20.0000 milligram (mg), Ph. Eur Inactive; Magnesium Stearate =6.0000 milligram (mg), Ph. Eur, Inactive; Hypromellose 2910 = 4.0000 milligram (mg), Ph. Eur Inactive; Copovidone Plasdone S630 = 3.6000 milligram (mg), Ph. Eur Inactive; Polyethylene Glycol 3350 =1.5200 milligram (mg), Ph. Eur, Inactive; Polydextrose =2.4000 milligram (mg), Ph. Eur Inactive;

	Caprylliccapric triglycerides =0.4800 milligram (mg), Ph. Eur, Inactive; Titanium dioxide =3.5300 milligram (mg), Ph. Eur, Inactive; Iron oxide yellow =0.3700 milligram (mg), Inactive; Iron oxide red =0.0700 milligram (mg), Inactive; Iron oxide black/Ferrosoferric Oxide =0.0300 milligram (mg), Inactive Capivasertib =200.0000 milligram(mg),In House Specification, Active; Microcrystalline cellulose =160.5000 milligram (mg), Ph. Eur, Inactive; Calcium hydrogen phosphate/Dibasic calcium phosphate =107.0000 milligram (mg), Ph. Eur Inactive; Croscarmellose Sodium =25.0000 milligram (mg), Ph. Eur, Inactive; Magnesium Stearate =7.5000 milligram (mg), Ph. Eur, Inactive; Hypromellose 2910 =4.7900 milligram (mg), Ph. Eur, Inactive; Copovidone Plasdone S630 =4.3100 milligram (mg), Ph. Eur, Inactive; Polyethylene Glycol 3350 =1.8200 milligram (mg), Ph. Eur, Inactive; Polydextrose =2.8700 milligram (mg), Ph.Eur, Inactive; Caprylliccapric triglycerides =0.5700 milligram (mg), Ph. Eur, Inactive; Titanium dioxide =4.2300 milligram (mg), Ph. Eur, Inactive; Iron oxide yellow =0.4500 milligram (mg), Inactive; Iron oxide red =0.0800 milligram (mg), Inactive; Iron oxide black/Ferrosoferric Oxide= 0.0300 milligram(mg), Inactive
Indications:	Adult participants with locally advanced (inoperable) or metastatic hormone receptor positive HR+/HER2- breast cancer with recurrence or progression on or after endocrine therapy

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Department of Medical Oncology, Jawaharlal Institute of Post-graduate Medical Education & Research (JIPMER), Dhanvantri Nagar, Gorimedu, Puducherry – 605006, India	IEC Intervention Studies JIPMER, Jawaharlal Institute of Post-graduate Medical Education & Research (JIPMER), Dhanvantri Nagar, Gorimedu, Puducherry – 605006, India ECR/342/Inst/PY/2013/RR-19	Dr. Biswajit Dubashi
2.	Department of Medical Oncology, Sri Ram Cancer & Super Speciality Centre, Mahatma Gandhi Medical College & Hospital (A Unit of Mahatma Gandhi Medical University of Medical Sciences &	Institutional Ethics Committee, Mahatma Gandhi Medical College & Hospital, RIICO Institutional Area, Tonk Road, Sitapura, Jaipur, SANGANER, Jaipur, Rajasthan - 302022, India ECR/125/Inst/RJ/2013/RR-19	Dr. Prashant Kumbhaj

	Technology), RIICO Institutional Area, Tonk Road, Sitapura, Jaipur - 302022, Rajasthan, India		
3.	Bhagwan Mahaveer Cancer Hospital & Research Centre, Jawahar Lal Nehru Marg, Jaipur - 302017, Rajasthan, India	Institutional Ethics Committee, Bhagwan Mahaveer Cancer Hospital & Research Centre, Jawahar Lal Nehru Marg, Jaipur - 302017, Rajasthan, India ECR/19/Inst/RJ/2013/RR-20	Dr. Aseem Kumar Samar
4.	HCG - Bharath Hospital and Institute of Oncology, (A Unit of Sada Sharada Tumor & Research Institute), No. 438, 1st Stage, Outer Ring Road, Hebbal Industrial Area, Hebbal, 1st Stage, Lakshmikanth Nagar Mysuru (Mysore) - 570 017, Karnataka, India	Institutional Ethics Committee, HCG –BHIO, Bharath Hospital and Institute of Oncology, No. 438, 1st Stage, Outer Ring Road, Hebbal Industrial Area, Lakshmikanth Nagar Mysuru (Mysore) - 570017, Karnataka, India ECR/994/Inst/KA/2017/RR-21	Dr. Srinivas K.G
5.	Kailash Cancer Hospital & Research Centre, Muni Seva Ashram, Goraj, Waghodiya, Vadodara - 391760, Gujarat, India	IEC - KCHRC, 1st Floor, Kailash Cancer Hospital & Research Centre, Department of Clinical Research, Goraj, Waghodiya, Vadodara - 391 760, Gujarat, India ECR/49/Inst/GJ/2013/RR-1	Dr. Santhosh Vandanasetti
6.	Indraprastha Apollo Hospitals, Sarita Vihar, Delhi - Mathura Road, Delhi - 110076, New Delhi, India	Institutional Ethics Committee - Clinical Studies, Indraprastha Apollo Hospitals, Sarita Vihar, Delhi - Mathura Road, Delhi - 110076, New Delhi, India ECR/5/Inst/DL/2013/RR-19	Dr. Manish Kumar Singhal
7.	Sri Sankara Cancer Hospital and Research Centre, 1st Cross, Shankara Matt Premises, Shankarapuram, Basavanagudi, Bangalore - 560004, Karnataka, India	Institutional Ethics Committee Sri Sankara Cancer Hospital and Research Centre, 1st Cross, Shankara Matt Premises, Shankarapuram, Basavanagudi, Bangalore - 560004, Karnataka, India ECR/1715/Inst/KA/2022	Dr. Vijai Simha

8.	Tata Medical Center,14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata - 700160, West Bengal, India	Institutional Review Board, Tata Medical Center,14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata - 700160, West Bengal, India ECR/269/Inst/WB/2013/RR-19	Dr. Joydeep Ghosh
9.	KIMS-Kingsway Hospitals, SPANV Medisearch Life Sciences Private Limited, 44, Parwana Bhawan, Kingsway, Nagpur - 440 001, Maharashtra, India	Kingsway Hospitals Ethics Committee, Kingsway Hospitals, 44, Parwana Bhawan, Kingsway, Nagpur - 440001, Maharashtra, India ECR/1269/INST/MH/2019	Dr. Mukesh Radheshyam Bang
10.	Mahamana Pandit Madan Mohan Malviya Cancer Centre (A Unit of Department of Atomic Energy, Govt. Of India) Sundar Bagiya, Near Nariya Gate, Banaras Hindu University Campus, Varanasi - 221 005, Uttar Pradesh, India	IEC, MPMMCC AND HBCH, Varanasi, Pandit Madan Mohan Malviya Cancer Centre, Sundar Bagiya, Near Nariya Gate, Banaras Hindu University Campus, Varanasi - 221 005, Uttar Pradesh, India ECR/1501/Inst/UP/2021	Dr. Akhil Kapoor
11.	Aakash Healthcare Super Speciality Hospital, Hospital Plot, Road No. 201, Dwarka Sector-3, New Delhi -110075, India	Aakash Healthcare Super Speciality Hospital Institutional Ethics Committee, Service Floor, Aakash Healthcare Hospital Plot, Road No. 201, Dwarka Sector-3, New Delhi-110075, India ECR/1265/Inst/DL/2019	Dr. Parveen Jain
12.	Max Super Speciality Hospital, Near Civil Hospital, Phase-6, Mohali, Punjab-160055, India	Institutional Ethics Committee (ICEC), Max Super Speciality Hospital (A Unit of Hometrail Buildtech Pvt. Ltd),Near Civil Hospital, Chandigarh Road, Phase VI, Mohali Punjab – 160055, India ECR/691/Inst/PB/2014/RR-21	Dr. Gautam Goyal

****